Oksaliplatin Kalceks (Oxaliplatin)

Oxaliplatin, the active ingredient in Oksaliplatin Kalceks, is a platinum‑based chemotherapy presented as a sterile injectable solution for intravenous use. It treats colorectal cancer and other solid tumours in adult patients, often in combination regimens.

GNH USA supplies Oksaliplatin Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality and regulatory compliance through rigorous quality control and validated manufacturing processes.

Oxaliplatin is a platinum‑based chemotherapeutic used in the treatment of gastrointestinal malignancies.

- Colorectal cancer: used in combination regimens (e.g., FOLFOX) to improve progression‑free and overall survival. - Gastric cancer: incorporated into combination therapy to enhance response rates in advanced disease. - Pancreatic cancer: employed in selected protocols to increase tumor control and survival outcomes.

Oxaliplatin is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Peripheral neuropathy (tingling or numbness) - Fatigue - Diarrhea - Neutropenia (low white blood cells)

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Pulmonary toxicity (interstitial pneumonitis) - Febrile neutropenia (infection with low neutrophils) - Thrombocytopenia (low platelets) - Hepatic dysfunction (elevated liver enzymes) - Tumor lysis syndrome (rare)

When using oxaliplatin, several precautionary measures should be observed to minimize risks. - Renal function monitoring: assess serum creatinine and creatinine clearance before and during therapy. - Hepatic function monitoring: check liver enzymes and bilirubin regularly. - Neuropathy assessment: evaluate for signs of peripheral neuropathy and adjust dose if needed. - Hypersensitivity risk: be prepared to manage acute infusion reactions with emergency medications. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin may interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage. - Neurotoxic drugs (e.g., vincristine, paclitaxel): exacerbate peripheral neuropathy. - Myelosuppressive chemotherapy (e.g., cyclophosphamide): heighten risk of severe bone‑marrow suppression. - High‑dose folinic acid: may potentiate oxaliplatin toxicity. - Anticoagulants (e.g., warfarin): increased bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may affect renal function. - ACE inhibitors or ARBs: monitor blood pressure and renal parameters. - Proton pump inhibitors: possible alteration of drug absorption (though limited for IV). - Antiepileptic drugs (e.g., carbamazepine): may affect hepatic metabolism. - Live attenuated vaccines: consider timing due to immunosuppression.